Opendata, web and dolomites

ImmuneCheckpointsAD SIGNED

Immune checkpoint blockade for fighting Alzheimer’s disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImmuneCheckpointsAD project word cloud

Explore the words cloud of the ImmuneCheckpointsAD project. It provides you a very rough idea of what is the project "ImmuneCheckpointsAD" about.

emphasizes    cognitive    2015    models    modification    pioneering    escalating    made    pathology    transient    tools    mouse    directed    led    ultimate    immune    disease    mitigate    2014    generation    supports    repair    multidisciplinary    blockade    discovery    assists    prevent    suppression    converting    discover    cellular    disposal    western    reversal    immunity    borders    selective    death    lost    prevention    brain    pd    expertise    goals    untreatable    responsible    restricted    reverse    understanding    stages    immunological    molecular    alzheimer    accomplished    dysfunction    risk    awry    checkpoint    medicine    ad    2016    empower    attain    experimental    neurons    ultimately    science    additional    maintenance    programmed    mechanisms    discoveries    communications    treating    nature    pave    immunotherapy    interface    therapeutic    decline    modify    systemic    team    unknown    treatable    countries    paradigm    chronic    attributing    treatment    genomic   

Project "ImmuneCheckpointsAD" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙287˙500 €
 EC max contribution 2˙287˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 2˙287˙500.00

Map

 Project objective

Understanding, and ultimately treating Alzheimer’s disease (AD) is a major need in Western countries. Currently, there is no available treatment to modify the disease. Several pioneering discoveries made by my team, attributing a key role to systemic immunity in brain maintenance and repair, and identifying unique interface between the brain’s borders through which the immune system assists the brain, led us to our recent discovery that transient reduction of systemic immune suppression could modify disease pathology, and reverse cognitive loss in mouse models of AD (Nature Communications, 2015; Nature Medicine, 2016; Science, 2014). This discovery emphasizes that AD is not restricted to the brain, but is associated with systemic immune dysfunction. Thus, the goal of addressing numerous risk factors that go awry in the AD brain, many of which are -as yet- unknown, could be accomplished by immunotherapy, using immune checkpoint blockade directed at the Programmed-death (PD)-1 pathway, to empower the immune system. In this proposal, we will adopt our new experimental paradigm to discover mechanisms through which the immune system supports the brain, and to identify key/novel molecular and cellular processes at various stages of the disease that are responsible for cognitive decline long before neurons are lost, and whose reversal or modification is needed to mitigate AD pathology, and prevent cognitive loss. Achieving our goals requires the multidisciplinary approaches and expertise at our disposal, including state-of-the art immunological, cellular, molecular, and genomic tools. The results will pave the way for developing a novel next-generation immunotherapy, by targeting additional selective immune checkpoint pathways, or identifying a specific immune-based therapeutic target, for prevention and treatment of AD. We expect that our results will help attain the ultimate goal of converting an escalating untreatable disease into a chronic treatable one.

 Publications

year authors and title journal last update
List of publications.
2019 Neta Rosenzweig, Raz Dvir-Szternfeld, Afroditi Tsitsou-Kampeli, Hadas Keren-Shaul, Hila Ben-Yehuda, Pierre Weill-Raynal, Liora Cahalon, Alex Kertser, Kuti Baruch, Ido Amit, Assaf Weiner, Michal Schwartz
PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-08352-5
Nature Communications 10/1 2020-02-13
2019 A. Kertser, K. Baruch, A. Deczkowska, A. Weiner, T. Croese, M. Kenigsbuch, I. Cooper, M. Tsoory, S. Ben-Hamo, I. Amit, M. Schwartz
Corticosteroid signaling at the brain-immune interface impedes coping with severe psychological stress
published pages: eaav4111, ISSN: 2375-2548, DOI: 10.1126/sciadv.aav4111
Science Advances 5/5 2020-02-13
2020 Michal Schwartz, Javier M. Peralta Ramos, Hila Ben-Yehuda
A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer’s Disease
published pages: 243-250, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1900844
The Journal of Immunology 204/2 2020-02-13
2018 Aleksandra Deczkowska, Ido Amit, Michal Schwartz
Microglial immune checkpoint mechanisms
published pages: 779-786, ISSN: 1097-6256, DOI: 10.1038/s41593-018-0145-x
Nature Neuroscience 21/6 2019-10-09
2018 Aleksandra Deczkowska, Michal Schwartz
Targeting neuro–immune communication in neurodegeneration: Challenges and opportunities
published pages: 2702-2704, ISSN: 0022-1007, DOI: 10.1084/jem.20181737
The Journal of Experimental Medicine 215/11 2019-06-05
2018 Aleksandra Deczkowska, Hadas Keren-Shaul, Assaf Weiner, Marco Colonna, Michal Schwartz, Ido Amit
Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
published pages: 1073-1081, ISSN: 0092-8674, DOI: 10.1016/j.cell.2018.05.003
Cell 173/5 2019-06-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNECHECKPOINTSAD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNECHECKPOINTSAD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SUBMODULAR (2019)

The Power of Randomness and Continuity in Submodular Optimization

Read More  

CARBOFLOW (2020)

Streamlined carbon dioxide conversion in ionic liquids – a platform strategy for modern carbonylation chemistry

Read More